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The relative tissue activities of pantothenate kinase range from 1 to 5 nmol.min-l .g-1 wet wt for heart, 
brain, kidney, and liver. The enzyme partially purified from each tissue is inhibited by CoA, but there is 
a IO-fold greater potency of inhibition of the heart enzyme compared to those from the other tissues. With 
the heart and liver enzyme, this difference in potency of CoA inhibition may be a reflection of the differing 
cytosolic CoA concentrations i  these tissues. L-Camitine speciiically reversed the inhibition of each enzyme 
by CoA. It is concluded that L-camitine may be a regulator of CoA synthesis ineach tissue. 
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1. INTRODUCTION 
Pantothenate kinase (ATP : D-pantothenate 
4’-phosphotransferase, EC 2.7.1.33) was initially 
found in bacteria [ 11, rat liver and kidney [2] and 
identified as the first enzyme in the pathway of 
CoA synthesis [3]. Recently, the enzyme was 
shown to be the rate-limiting step for CoA syn- 
thesis in perfused hearts [4]. There are no reports 
of the relative activities of pantothenate kinase in 
different tissues, but some properties have been 
described for the isolated enzyme. CoA is an in- 
hibitor of pantothenate kinase from liver and 
kidney [5-71 and may therefore be a feedback in- 
hibitor of its own synthesis. In studies of the en- 
zyme from heart, we have also found CoA to be an 
inhibitor (unpublished), but with a much greater 
potency of inhibition than is reported for the liver 
and kidney enzyme. In addition, we found that L- 
carnitine could specifically reverse the inhibition of 
the heart enzyme by CoA. These properties of the 
heart enzyme could suggest tissue-specific varia- 
* To whom correspondence should be addressed 
tion in the properties of pantothenate kinase. Thus 
the aims of our experiments were to measure the 
relative activities of pantothenate kinase in dif- 
ferent tissues of the rat, determine the potencies of 
inhibition by CoA, and examine the effects of L- 
carnitine on this inhibition. 
2. MATERIALS AND METHODS 
2.1. Materials 
Substrates, creatine kinase, DTT, CoA and 
Dowex 1X8-400 (chloride form) were from Sigma. 
L- and D-carnitine (inner salts) were from Sigma 
Tau, Italy. PD 10 desalting columns were from 
Pharmacia. D-[‘HlPantothenate (1.1 Ci/mmol) 
and ACS 11 scintillation fluid were from Amer- 
sham. All other chemicals were reagent grade or 
better. 
2.2. Tissue extraction 
l-4 g of heart, brain, liver or kidney from male 
Sprague-Dawley rats (200-300 g) were extracted in 
4 vols cold buffer using a Polytron (Brinkman In- 
struments) at 40% maximum speed. The buffer 
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consisted of 20 mM Mops, 0.5 mM EDTA, 2 mM 
DTT and 0.25 M sucrose, pH 7. Homogenates 
were centrifuged at 30000 x g for 40 min, and the 
supernatants collected. In a separate experiment, 
the individual supernatants were fractionated be- 
tween 35 and 50% saturation with solid 
(NH&S04, the precipitate redissolved and 
desalted by gel filtration on PD 10 columns. 
2.3. Partial purification of pantothenate kinase 
Tissues from 8 rats were pooled, and extracted 
and centrifuged as described above. The super- 
natants were treated with 0.035 vol. of 2% pro- 
tamine sulfate solution [5] and the precipitates 
removed by centrifugation. The protamine-treated 
supernatants were then fractionated between 35 
and 50% saturation with solid (NH4)2S04, and the 
fractions redissolved and precipitated to 50% 
saturation. The final precipitates were desalted 
after dissolution in extraction buffer, and stored in 
batches at -20°C. The apparent purification and 
recoveries were: heart, 6-fold and 82%; brain, 
11-fold and 50%; kidney, 2.5-fold and 36%; and 
liver, 2-fold and 36%. 
2.4. Pantothenate kinase assay 
The reaction mixture (0.1 ml) consisted of 
50 mM triethanolamine, 10 mM DTT, 4 mM 
ATP, 6 mM MgC12, 10 mM creatine phosphate, 
15 U/ml creatine kinase, and 55 PM D-pantothe- 
nate containing 5 &i D-[3H]pantothenate/m1, at 
pH 7. Other additions are as shown in the tables 
and figure. Solutions of CoA were made in the 
presence of 10 mM DTT to prevent oxidation. The 
reaction at 37°C was for 20-40 min and was 
stopped by the addition of 0.2 ml cold methanol. 
A portion (0.2 ml) of the supernatant after cen- 
trifugation was transferred to a small anion- 
exchange resin column and washed with 1 ml 
deionised water. The column (5 x 50 mM, Kontes) 
contained Dowex 1X8 to a height of 15 mm. 
Labeled pantothenate was eluted with 4 ml of 
0.1 M NaCl and then labeled 4 ’ -phosphopanto- 
thenate was collected directly into a scintillation 
vial by elution with 2 ml of-O.25 M HCl. Radioac- 
tivity in vials was measured after the addition of 
15 ml ACS 11. Progress curves were linear for the 
time of reaction and activity was calculated from 
the fractional conversion of substrate to product. 
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3. RESULTS AND DISCUSSION 
Pantothenate kinase is located in the cytosol 
[7,8] and activities measured in this fraction range 
from 1 to 5 nmol e min-’ *g-r wet wt for heart, 
brain, kidney and liver (table 1). The activity of the 
kinase in crude supernatant extracts from heart is 
suppressed since ammonium sulfate fractionation 
of the supernatant reveals a markedly higher ac- 
tivity (table 1, columns 1,3). The addition of L- 
carnitine to assays of the crude supernatant ex- 
tracts of heart also leads to a greater expression of 
kinase activity (table 1, column 2) and it will be 
shown that this apparent activation is likely to be 
due to a reversal of inhibition. The activity of the 
kinase expressed in crude supernatant extracts 
from brain, kidney and liver is not markedly af- 
fected by the presence of L-carnitine in the assays 
(table 1, columns 1,2) and for kidney and liver, ac- 
tivities revealed after ammonium sulfate fractiona- 
tion are similar to those of the crude supernatants 
(table 1, column 3). These tissue activities of the 
kinase are more than sufficient to account for the 
rates of CoA synthesis measured in vivo. Based on 
the rate of incorporation of labeled pantothenate 
after injection into rats, the rates of CoA synthesis 
Table 1 
The relative activities of pantothenate kinase in various 
tissues of the rat 
Tissue Enzyme activity 
(nmol.min-‘.g-’ wet wt) 
Crude supernatant 
+ 10 mM L-carnitine 
Ammonium 
sulfate 
fraction 
- + 
Heart 0.44 + 0.06 1.33 2 0.15 2.02 f 0.24 
Brain 1.38 + 0.05 1.56 f 0.08 ND 
Kidney 2.09 k 0.18 2.66 f 0.19 2.67 + 0.15 
Liver 3.71 +_ 0.22 5.29 + 0.25 4.08 + 0.12 
Kinase activity was assayed in crude supernatant extracts 
of tissue with and without addition of L-carnitine to the 
assays. Kinase activity was also assayed in extracts after 
ammonium sulfate fractionation to remove soluble 
metabolites. Activities are given as mean + SE and n = 
5 for crude supernatants, n = 4 for ammonium sulfate 
fractions. ND, not determined 
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range from 0.03 to 0.23 nmol.min-‘*g-l for 
heart, kidney and liver [9,10]. 
Previously, it was reported that pantothenate 
kinase partially purified from liver and kidney is 
inhibited by CoA [5-71. The kinase partially 
purified from heart and brain is also inhibited by 
CoA, but there is a more than lo-fold greater 
potency of inhibition of the heart enzyme com- 
pared to that from the other tissues (fig.1). Under 
the conditions of assay, concentrations of CoA 
giving 50% inhibition (ZSO) are 0.08 pM for the 
heart enzyme compared to 1.7, 2.2 and 3.1 ,uM, 
respectively, for the enzyme from kidney, liver and 
brain. It is likely that pantothenate kinase is 
strongly inhibited in vivo by the CoA that is pre- 
sent in the cytosol. For instance, the total CoA 
concentration of the cytosol of heart is 14 BM [l l] 
and that of the liver 186 PM [ 121. These cytosolic 
CoA concentrations are lOO-fold higher than the 
ZSO for the inhibition of the respective nzymes. A 
proportion of this cytosolic CoA will be present as 
acyl esters, but these are also inhibitors of the 
kinase from each tissue ([6,7] and unpublished). 
The similarity in the ratio of cytosolic CoA con- 
[CoA] (JJM) 
Fig. 1. Inhibition of pantothenate kinase by CoA. 
Pantothenate kinase isolated from (0) ,heart, (A) 
kidney, (0) liver and (w) brain was assayed in the 
presence of increasing concentrations of CoA. Activities 
relative to the control activity are plotted vs a log scale 
of CoA concentration. The control specific activities 
were heart, 0.35; brain, 0.62; kidney, 0.16; and liver, 
0.11 nmol.min-‘.mg-’ protein. 
centration to Iso for heart and liver but the 
markedly differing Iso probably indicates tissue- 
specific variation in this particular property of 
pantothenate kinase. 
L-Carnitine, the naturally occurring isomer, is 
found in varying quantities in every tissue exam- 
ined [ 131. By itself, L-carnitine has no effect on the 
activity of pantothenate kinase partially purified 
from heart, brain, kidney and liver (table 2). 
However, it appears to reverse specifically the in- 
hibition by CoA of the enzyme from each source 
(table 2). The specificity of this property is shown 
by the lack of any effect of D-carnitine on the en- 
zyme whether it is inhibited by CoA or not (table 
2). 
The physiological significance of this effect of 
L-carnitine will require a more detailed study of 
this property of pantothenate kinase than is pro- 
vided here. However, the cellular function of L- 
Table 2 
Effect of L-carnitine on the inhibition of pantothenate 
kinase from various tissues by CoA 
Tissue CoA Relative activity (?‘o) 
W) 
Added carnitine (mM) 
L-Carnitine D-Carni- 
tine 
0 1 10 10 
Heart 0 100 104 103 97 
0.1 44 56 64 43 
0.25 23 34 43 19 
Brain 0 100 101 100 101 
2.5 61 64 70 60 
5.0 36 43 48 37 
Kidney 0 100 101 101 105 
2.5 33 62 72 35 
Liver 0 100 106 105 105 
2.5 48 61 71 47 
The kinase partially purified from each tissue was 
assayed in the absence and presence of CoA, and with 
the concentrations of carnitine indicated. Activities are 
given relative to that obtained in the absence of 
additions, and are the mean of 2 experiments. The 
control specific activities were: heart, 0.35; brain, 0.64; 
kidney, 0.15; and liver, 0.11 nmol.min-‘-mg-’ protein 
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carnitine and CoA are linked through the exchange 
of acyl units between the 2 cofactors so that car- 
nitine can facilitate the translocation of the acyl 
unit across the inner mitochondria1 membrane 
f14j. The apparent universality of the effect of L- 
carnitine on CoA inhibition of pantothenate 
kinase suggests that there is a second link between 
carnitine and CoA in that carnitine may act to 
regulate the synthesis of CoA. 
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